目的：分析11例（慢性淋巴细胞白血病（CLL）合并t（14;19）（q32;q13））的临床病理特征。方法：回顾性分析中国医学科学院血液病医院2018年1月1日至2022年7月30日的11例CLL合并t（14; 19）（q32;q13）的染色体核型分析结果，包括患者基本资料。结果：在所有11例患者中，t（14; 19）（q32;q13）涉及IGH::BCL3基因重排，并且大部分患者伴有+12染色体异常或复杂核型。在7例患者中发现免疫表型得分为4-5，而4例患者中为3。我们证明，CLL合并t（14;19）（q32;q13）在重复突变中具有NOTCH1（3/7）、FBXW7（3/7）和KMT2D（2/7）的突变模式。非常高风险组、高风险组、中风险组和低风险组分别有1例、1例、6例和3例。两例患者死亡，8例患者存活，2例患者失去随访。4例患者在治疗过程中出现疾病进展或复发。第一次治疗的中位时间为1个月。结论：涉及IGH::BCL3基因重排的t（14;19）（q32;q13）是CLL中罕见的复发性细胞遗传异常，与预后较差有关。

Objective: To analyze the clinicopathological characteristics of 11 cases of chronic lymphocytic leukemia (CLL) with t (14;19) (q32;q13) . Methods: The case data of 11 patients with CLL with t (14;19) (q32;q13) in the chromosome karyotype analysis results of the Blood Diseases Hospital, Chinese Academy of Medical Sciences from January 1, 2018, to July 30, 2022, were retrospectively analyzed. Results: In all 11 patients, t (14;19) (q32;q13) involved IGH::BCL3 gene rearrangement, and most of them were accompanied by +12 or complex karyotype. An immunophenotypic score of 4-5 was found in 7 patients and 3 in 4 cases. We demonstrated that CLLs with t (14;19) (q32;q13) had a mutational pattern with recurrent mutations in NOTCH1 (3/7), FBXW7 (3/7), and KMT2D (2/7). The very-high-risk, high-risk, intermediate-risk, and low-risk groups consisted of 1, 1, 6, and 3 cases, respectively. Two patients died, 8 survived, and 2 were lost in follow-up. Four patients had disease progression or relapse during treatment. The median time to the first therapy was 1 month. Conclusion: t (14;19) (q32;q13), involving IGH::BCL3 gene rearrangement, is a rare recurrent cytogenetic abnormality in CLL, which is associated with a poor prognosis.